A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11

NCT01663441 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Chemotherapy-induced Thrombocytopenia

Interventions

DRUG: NL201
DRUG: NL201
DRUG: NL201
DRUG: rhIL-11

Sponsor

Beijing Northland Biotech. Co., Ltd.